Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
Status:
Completed
Trial end date:
2017-07-21
Target enrollment:
Participant gender:
Summary
Vabomere™, (meropenem-vaborbactam) is being compared to the Best Available Therapy in the
treatment of adults with selected serious infections due to Carbapenem Resistant
Enterobacteriaceae
Phase:
Phase 3
Details
Lead Sponsor:
Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.) Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)